# THEO-260

Source: https://onco.cc/drugs/theo-260/  
OnCo record `theo-260` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.

## Summary

THEO-260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Theolytics Limited, in ovarian cancer. An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: THEO-260
- Modality: Oncolytic virus
- Mechanism: An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system.

## Sources

- ClinicalTrials.gov: trials of THEO-260: https://clinicaltrials.gov/search?intr=THEO-260

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- trials: [Trial of THEO-260 in Ovarian Cancer Patients](https://onco.cc/trials/nct06618235/)

---
JSON: https://onco.cc/api/v1/entities/theo-260.json